法匹拉韦治疗新型冠状病毒肺炎的可行性分析

Feasibility of Favipiravir in the Treatment of the Coronavirus Disease 2019

目的 探讨法匹拉韦治疗新型冠状病毒肺炎(COVID-19)的临床可行性。方法 针对从已上市/已进入临床研究的药物中挖掘出的、可能具有抗新型冠状病毒(SARS-CoV-2)作用的药物之一法匹拉韦,结合其作用机制、临床应用史和临床疗效及安全性试验进行可行性分析。结果 与结论法匹拉韦为国内首个在疫情期间批准上市的抗病毒药物,适应证为成人新型或再次流行的流感。经可行性分析,其对多种RNA病毒疗效显著,且不良反应也较少,从理论上对SARS-CoV-2也有作用,但有待更大规模的临床试验进行验证。

Objective To investigate the clinical feasibility of favipiravir in the treatment of the coronavirus disease 2019(COVID-19).Methods Favipiravir is one of the drugs that may have anti-severe acute respiratory syndrome-coronavirus-2(SARS-CoV-2)effects discovered from the drugs on the market or in the clinical research,the feasibility analysis of favipiravir was carried out through its mechanism of action,clinical application history,clinical efficacy and safety test.Results and Conclusion Favipiravir is the first antiviral drug approved to be marketed in China during the COVID-19 epidemic,and its indication is novel or re-prevalent influenza in adults.According to the feasibility analysis,it has a significant effect on a variety of RNA viruses with few adverse reactions,and it also has a theoretical effect on the SARS-CoV-2,but it needs to be verified in a larger clinical trial.